Recently, TrialSite News initiated a research project that offers patients and sponsorsvaluable information regarding many clinical investigation sites. This information isn’t easily found, but our researchers believe transparency is the most important component to our readers. While investigating clinical research sites treating metastatic castration resistant prostate cancer, we first covered Pacific Hematology Oncology Associates. Next up is a review of San Bernardino Urological Associates, who are part of the same clinical trial.
About San Bernardino Urological Associates
San Bernardino Urological Associates has two locations—one in San Bernardino and one in Apple Valley. According to their website, they have been serving Inland Empire since 1985. The physicians in their Group are committed to bringing the highest quality of urological medical care to their patients. Each of their physicians are Board Certified Urologists. Through extensive training and continued medical education, it is their goal to deliver state of the art, evidence-based care to their patients.
Clovis Oncology, Inc. is sponsoring this study, officially titled “TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician’s Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency.” Founded in 2009, Clovis Oncology is a commercial stage biotechnology company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets.
Clovis’ product development programs generally target specific subsets of cancer, and the Company seeks to simultaneously develop, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the patients most likely to benefit from their use. Through these collaborations, Clovis has the flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel Clovis’ regulatory and commercialization paths. Clovis believes this approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy.
Study Details and Participation
The actual study start date was in June 2017 and it’s estimated completion date is in April 2022. The estimated enrollment is 400 participants. It is currently recruiting participants, depending on location. San Bernardino Urological Associates is still in the recruiting phase.
Key Principal Investigator
The key principal investigator at San Bernardino Urological Associates is Franklin M. Chu M.D., F.A.C.S. Dr. Chu received his M.D. from Tulane University, New Orleans Louisiana 1979. He completed his Urology residency from UC Irvine in 1985. He is the founding member of San Bernardino Urological Associates Medical Group. He has been a Board Certified Urologist since 1987 and has been recertified in 1995 and 2006. He was a clinical faulty of UC Irvine Urology Department from 1985-1991. He has served as Chief of Surgery of both St. Bernardine Medical Center and Community Hospital of San Bernardino. He is a Fellow of American College of Surgeons as well as a member of the American Urological Association, California Urological Association and California Medical Association. He also received a M.S. in Physical Chemistry from the University of Illinois Champaign-Urbana.
Dr. Chu has served as chairman of St. Bernardine Medical Center’s Institution Review Board since 2000. He is also active in all areas of urology research, serving as primary investigator or sub-investigator on over 200 industry and federally funded clinical studies. He is the author of numerous peer reviewed articles on Prostate Cancer, Advanced Prostate Cancer, Overactive Bladder and Erectile Dysfunction. He also serves as a national advisor for multiple national and international pharmaceutical companies.
TrialSite News did not find any results on Dr. Chu when searched for in the FDA’s Clinical Investigator Inspection Search.
While we did not find any FDA Warning Letters or Inspections, TrialSite News researchers came across stipulations that Dr. Franklin M. Chu and Dr. Daniel J. Lama were involved in insider trading. Click here for details on the cases. In addition, Dr. Chu’s google listing and Dr. Lama’s google listing both had reviews that were uninspiring, to say the least. San Bernardino Urological Associates also has two google listings, here and here, that both had low ratings. Their Yelp page only has two stars, and their unofficial Facebook page has little information.
Call to Action: Have you been diagnosed with prostate cancer and are in California looking for treatment? We recommend that for more Clinical Investigation Site reviews, make sure to sign up for TrialSite News’ Daily Digest.